On August 4th, the U.S. Food and Drug Administration (FDA) approved zuranolone, the first oral medication designed to treat postpartum depression (PPD) in adults. The drug, which is rapid-acting, was…
Read More
Researchers have reported progress in the important effort to explain the rapid antidepressant action of ketamine, and in so doing, have gained insights that may inform the development of other…
Read More
The experimental drug ketamine has been shown to reduce symptoms of major depression, even in treatment-resistant patients, within hours of a single intravenous administration. A medicine based on…
Read More
The experimental drug ketamine has been shown to reduce symptoms of major depression, even in treatment-resistant patients, within hours of a single intravenous administration. A medicine based on…
Read More
An investigational medicine called zuranolone has generated significant, rapid, and enduring symptom reduction in women with postpartum depression. The drug was compared with placebo in a phase 3…
Read More